Deborah Denisse Gaibor Santos
Deborah Denisse Gaibor Santos has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Gabriel Leon San Miguel2 shared publications
- María Fernanda Calderón León
Hospital Universitario de Guayaquil, Ecuador
2 shared publications Andrea Patricia Chancay Mendoza
1 shared publicationCésar Oswaldo Loor Loor
1 shared publication- Diego Mauricio Cabrera Moyano1 shared publication
- Javier Aquiles Hidalgo Acosta
Hospital General Dr. Enrique Ortega Moreira, Durán, Ecuador
1 shared publication
Latest Publications
- Open Access
- 26 November 2025
- Published by IntechOpen
Polycystic Ovary Syndrome: A Therapeutic Challenge
It is often a therapeutic challenge to manage polycystic ovary/ovarian syndrome (PCOS), as it is a pathology that affects both the metabolic and endocrine systems, generating problems associated with insulin resistance, obesity, and biopsychosocial problems mainly in adolescents and women in the reproductive stage. It affects between 5% and 18% of women of childbearing age. Its etiology is heterogeneous, and its definitive cause is still unknown. Therefore, treatment will depend on each patient’s symptoms and individual preferences. It is a common cause of anovulatory infertility in 75% of cases. The objective of this research was to determine the therapeutic challenges of PCOS, for which we reviewed high-level scientific medical articles published in databases such as PubMed, Cochrane, Latindex, Elsevier, Google Scholar, and Embase, concluding that symbiotic supplementation improves several clinical and laboratory aspects of PCOS, including an improvement in hyperandrogenism and lipid profile. In patients with PCOS resistant to treatment with clomiphene citrate (CC), the addition of human chorionic gonadotropin (HCG) at low doses would be an effective method to improve ovulation and, therefore, fertility. The combination of letrozole and clomiphene is superior to either drug separately for ovulation induction in PCOS. Surgical treatment is an option for patients resistant to medical treatment and is performed by laparoscopic or transvaginal ovarian drilling.
- 26 November 2025
- Published by IntechOpen
Open AccessPolycystic Ovary Syndrome: A Therapeutic Challenge
It is often a therapeutic challenge to manage polycystic ovary/ovarian syndrome (PCOS), as it is a pathology that affects both the metabolic and endocrine systems, generating problems associated with insulin resistance, obesity, and biopsychosocial problems mainly in adolescents and women in the reproductive stage. It affects between 5% and 18% of women of childbearing age. Its etiology is heterogeneous, and its definitive cause is still unknown. Therefore, treatment will depend on each patient’s symptoms and individual preferences. It is a common cause of anovulatory infertility in 75% of cases. The objective of this research was to determine the therapeutic challenges of PCOS, for which we reviewed high-level scientific medical articles published in databases such as PubMed, Cochrane, Latindex, Elsevier, Google Scholar, and Embase, concluding that symbiotic supplementation improves several clinical and laboratory aspects of PCOS, including an improvement in hyperandrogenism and lipid profile. In patients with PCOS resistant to treatment with clomiphene citrate (CC), the addition of human chorionic gonadotropin (HCG) at low doses would be an effective method to improve ovulation and, therefore, fertility. The combination of letrozole and clomiphene is superior to either drug separately for ovulation induction in PCOS. Surgical treatment is an option for patients resistant to medical treatment and is performed by laparoscopic or transvaginal ovarian drilling.
- Open Access
- 24 October 2025
- Published by IntechOpen
Alteration of Fetal Growth
Fetal growth is a process that is not easy to assess and is regulated by multiple mechanisms that depend on many fetal, placental, and maternal factors. The birth weight percentile compared to the estimated gestational age reveals lower gestational ages for women and higher gestational ages for men in certain geographic areas such as Africa, with differences in comparison with the world population. The alteration in fetal growth is related to several perinatal complications such as intrauterine death, increased cesarean section, maternal-neonatal injuries, and shoulder dystocia. Among the main manifestations of fetal growth disturbance is intrauterine fetal growth restriction, which affects approximately 3–7% of all pregnancies and is defined as a condition in which the fetus fails to achieve the growth determined by its genetic makeup. Its diagnosis requires an estimated fetal weight by ultrasound lower than the 10th percentile for gestational age. The most outstanding maternal risk factor for fetal growth disturbance is maternal body mass index, where obesity predominates. Asymmetric or type II intrauterine growth restriction is more frequent in the second trimester of pregnancy.
- 24 October 2025
- Published by IntechOpen
Open AccessAlteration of Fetal Growth
Fetal growth is a process that is not easy to assess and is regulated by multiple mechanisms that depend on many fetal, placental, and maternal factors. The birth weight percentile compared to the estimated gestational age reveals lower gestational ages for women and higher gestational ages for men in certain geographic areas such as Africa, with differences in comparison with the world population. The alteration in fetal growth is related to several perinatal complications such as intrauterine death, increased cesarean section, maternal-neonatal injuries, and shoulder dystocia. Among the main manifestations of fetal growth disturbance is intrauterine fetal growth restriction, which affects approximately 3–7% of all pregnancies and is defined as a condition in which the fetus fails to achieve the growth determined by its genetic makeup. Its diagnosis requires an estimated fetal weight by ultrasound lower than the 10th percentile for gestational age. The most outstanding maternal risk factor for fetal growth disturbance is maternal body mass index, where obesity predominates. Asymmetric or type II intrauterine growth restriction is more frequent in the second trimester of pregnancy.